Ticker Symbol | Entity Name | As Of Date | Company Name | Followers | Employees on Linkedin | Link | Industry | Date Added | Date Updated | Description | Website | Specialities | Logo | HQ.Street | HQ.City | HQ.State | HQ.Country | HQ.Postal | Headcount change in past 24 months | Company Name | Sector | Industry |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
private:neuronaxsas-2 | 1377992 | May 30th, 2019 12:00AM | NEURONAX | 272 | 4.00 | Open | Pharmaceuticals | May 30th, 2019 01:45PM | May 30th, 2019 01:45PM | NEURONAX is a privately-held biotech company focusing on the development of candidate-drugs for the treatment of traumatic or severe degenerative disorders of the central nervous system (CNS). NEURONAX focuses particular nervous disorders for which the capacities to treat patients are limited and the "unmet needs" are very important. Among them, injuries of the CNS are among the major clinical problems since the consequences are currently irreversible resulting in serious disabilities in sensory and motor function. Our most advanced product candidate, NX210, a neuro-protective and neuro-regenerative peptide, was deduced from a naturally secreted protein produced early during emryonic development by specialized ependymal cells located in the brain. This promising first-in-class candidate has been shown to improve recovery and neurological function and may adress treatment of various acute and chronic disorders, including but not limited to spinal cord injuries (SCI), traumatic brain injuries (TBI), stroke, Alzheimer or Parkinson’s diseases. For more information, please visit our website. | Open | neural repair, neuroprotection, spinal cord injury, neurodegenerative diseases, candidate-drug, preclinical, neuroregeneration, peptide, traumatic brain injury, stem cells, axon outgrowth | Open | 60 avenue Rockefeller | Lyon | FR | 69008 | Neuronax SAS | Pharmaceuticals & Biotechnology | |||
private:neuronaxsas-2 | 1377992 | Nov 7th, 2017 12:00AM | NEURONAX | 170 | 5.00 | Open | Pharmaceuticals | Nov 7th, 2017 05:28PM | Nov 7th, 2017 05:28PM | NEURONAX is a privately-held biotech company focusing on the development of candidate-drugs for the treatment of traumatic or severe degenerative disorders of the central nervous system (CNS). NEURONAX focuses particular nervous disorders for which the capacities to treat patients are limited and the "unmet needs" are very important. Among them, injuries of the CNS are among the major clinical problems since the consequences are currently irreversible resulting in serious disabilities in sensory and motor function. Our most advanced product candidate, NX210, a neuro-protective and neuro-regenerative peptide, was deduced from a naturally secreted protein produced early during emryonic development by specialized ependymal cells located in the brain. This promising first-in-class candidate has been shown to improve recovery and neurological function and may adress treatment of various acute and chronic disorders, including but not limited to spinal cord injuries (SCI), traumatic brain injuries (TBI), stroke, Alzheimer or Parkinson’s diseases. For more information, please visit our website. | Neuronax SAS | Pharmaceuticals & Biotechnology | ||||||||||
private:neuronaxsas-2 | 1377992 | Nov 1st, 2017 12:00AM | NEURONAX | 168 | 4.00 | Open | Pharmaceuticals | Nov 1st, 2017 05:10AM | Nov 1st, 2017 05:10AM | NEURONAX is a privately-held biotech company focusing on the development of candidate-drugs for the treatment of traumatic or severe degenerative disorders of the central nervous system (CNS). NEURONAX focuses particular nervous disorders for which the capacities to treat patients are limited and the "unmet needs" are very important. Among them, injuries of the CNS are among the major clinical problems since the consequences are currently irreversible resulting in serious disabilities in sensory and motor function. Our most advanced product candidate, NX210, a neuro-protective and neuro-regenerative peptide, was deduced from a naturally secreted protein produced early during emryonic development by specialized ependymal cells located in the brain. This promising first-in-class candidate has been shown to improve recovery and neurological function and may adress treatment of various acute and chronic disorders, including but not limited to spinal cord injuries (SCI), traumatic brain injuries (TBI), stroke, Alzheimer or Parkinson’s diseases. For more information, please visit our website. | Neuronax SAS | Pharmaceuticals & Biotechnology |